Before planned surgery, patients may choose autologous donation in order to avoid the small, but potential, risks of receiving an allogeneic blood transfusion. This study examined the perceived risks of allogeneic blood transfusions, preferences and willingness to pay for autologous donation and the desired role in the decision-making process in three populations: post-surgical patients, special interest group members and the general public. Quantitative and qualitative data were collected from 206 respondents with the help of computer-assisted semi-structured telephone interviews. Thirty-three per cent of the sample voiced concerns about receiving allogeneic blood transfusions. The risks of hepatitis C virus, human immunodeficiency virus, variant Creutzfeldt-Jakob disease and a haemolytic reaction were perceived as being low, but were rated as numerically higher than those of other life events that have equal probability. Autologous donation was perceived as removing all the risks associated with transfusion, and respondents were willing to pay a median $976 AUD ($664 US) to use this technique. Over 80% of respondents preferred to be involved in making the decision about whether to use autologous donation. Even though autologous donation is not 'risk-free' and the blood supply is very safe, people overestimate the associated risks and have a preference for their own blood. Decision aids presenting balanced information on the advantages and disadvantages of both allogeneic and autologous blood may be required.
Alzheimer's disease (AD) is a severe neurodegenerative disease which impacts the quality of life in elderly patients and imposes a significant burden to families and caregivers. The prolonged life expectancy and rapidly increasing world population significantly increased the morbidity. Although it has been widely reported that the aggregation of Beta amyloid and neurofilaments is the most significant pathological change.Currently, there is no effective drug therapy for AD, and the potential risks of pharmacotherapy remain concerns. This article reviews the recent research on Doll therapy (DT), a widely used non-drug therapy on AD patients, especially its clinical effectiveness and precautions in treating AD, with an attempt to further alleviate the mental symptoms and improve the health status of AD patients. Thus, nonpharmacological treatments of AD have become an area of intense research interest in recent years. DT is a person-centered therapy that can improve both the mental and cognitive status and the quality of life in AD patients.Although there remains ethical controversy about the DT on AD patients, its positive effect has been proved.Moreover, a standards manual is required to stipulate the range of application, the time course for treatment and withdraw the toy from the patients.
Objective In order to improve the efficiency and prediction accuracy of BP neural network for disease diagnosis, a genetic algorithm was proposed to optimize BP neural network for the diagnosis of Alzheimer's disease to verify the more practical and dementia diagnosis. Methods: Taking the electronic medical record data mining in hospital as an example, a predictive model was established for the diagnosis of Alzheimer's disease. The method firstly uses the genetic algorithm's search optimization technology to carry out feature reduction, and then uses the reduced feature as the input variable of BP neural network to train and construct the BP neural network model. The simulation experiment was carried out on the MATLAB software platform. Results: Compared with single BP neural network, genetic algorithm optimization BP neural network can reduce the training time of the model and improve the prediction accuracy. It is a feasible auxiliary diagnosis method for Alzheimer's disease. Conclusion: The application of hierarchical genetic algorithm GA‐RBF neural network system and early prediction of senile dementia and cognitive status can help to accurately predict the cognitive status of the elderly, prevent it in advance, and improve the quality of care for patients with Alzheimer's disease clinical promotion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.